Childhood vaccine schedule updated (w/ Video)

Jan 07, 2010

The co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases is a member of the committee that this week issued updated guidelines for childhood and teen immunizations to include formal recommendations that children older than 6 months get the H1N1 influenza vaccine to guard against swine flu, and that combination vaccines are generally preferred over separate injections.

The revised childhood vaccine schedule is published in the January issue of Pediatrics; the annual update is issued by the American Academy of Pediatrics, the and the American Academy of Family Physicians.

UAB's David Kimberlin, M.D., is a member of the American Academy of Pediatrics Committee on Infectious Diseases and a liaison to the Centers for Disease Control panel that helped author the recommendations.

This video is not supported by your browser at this time.
David Kimberlin, M.D. serves on the panel that released new childhood vaccine schedules. Credit: UAB

"Most of these recommendations are for vaccines and boosters that almost every pediatrician and family physician knows about and already is using. It is good practice to issue a clear, concise vaccine schedule that anyone can refer to," says Kimberlin, a UAB professor and associate editor of the American Academy of Pediatrics' Red Book, a revered pediatric treatment manual.

"The bottom line here is vaccines save lives, improve the health of all children and benefit families and communities," he says.

The updated schedule reflects new vaccines approved by the U.S. that include the H1N1 vaccine and a for girls, known as the HPV2 vaccine, designed to protect females from two strains of the virus associated with more than 70 percent of cervical cancer cases, says Kimberlin.

The new schedule states it is permissible for doctors to recommend the earlier HPV4 vaccine for boys ages 9 and older, offering protection from four strains of the virus and reducing the likelihood of male genital warts. The recommendations also say children considered at-risk for meningococcal disease, especially those with immune-system disorders and other conditions, should get a booster shot of meningococcal conjugate vaccine, known as MCV4, three years after their initial MCV4 dose at ages 2 through 6.

The update also says that after four scheduled doses of inactivated poliovirus vaccine, the fifth dose of the same vaccine should be given on or after age 4 and at least six months after the previous dose.

Kimberlin says vaccine considerations always should consider health-care provider assessment, patient preference and the potential for adverse events. Providers who need more details should refer to the comprehensive recommendations issued by the Centers for Disease Control Advisory Committee on Immunization Practices, available by clicking here. Clinically significant adverse events that follow immunization should be reported to the Adverse Event Reporting System at www.vaers.hhs.gov or 800-822-7967.

Explore further: Booming mobile health app market needs more FDA oversight for consumer safety, confidence

add to favorites email to friend print save as pdf

Related Stories

Medical societies: Adults need vaccines

Nov 19, 2008

The American College of Physicians (ACP) and the Infectious Diseases Society of America (IDSA) have released a joint statement on the importance of adult vaccination against an increasing number of vaccine-preventable diseases. ...

CDC concedes vaccine production behind schedule

Oct 21, 2009

(AP) -- A top-ranking official of the Centers for Disease Control and Prevention says production of a vaccine for swine flu virus is behind schedule and people should take precautionary steps to prevent its spread.

Recommended for you

Determine patient preferences by means of conjoint analysis

3 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

marky
not rated yet Jan 08, 2010
One needs to look at both side of the coin to form a balanced and informed opinion on the safe use of vaccines.
Therefore see also:
http://articles.m...see.aspx